GlycA, a composite biomarker of systemic inflammation, is associated with cardiovascular disease (CVD) and mortality, but its relationship with peripheral artery disease (PAD) is unknown. We assessed whether plasma GlycA is associated with ankle–brachial index (ABI), carotid plaque (CP), and incident clinical PAD among 6466 Multi-Ethnic Study of Atherosclerosis participants without CVD at baseline. GlycA, ABI, and CP were measured at baseline. Both ABI and CP were remeasured at 10 years. Incident clinical PAD was ascertained from hospital records. We used logistic, Cox, and linear mixed regression models adjusted for demographic and lifestyle factors. Mean (standard deviation, SD) was 62 (10) years for age and 381 (61) µmol/L for GlycA; 53% were women. GlycA was associated with both prevalent low ABI ≤0.8 (prevalence odds ratio [95% confidence interval, CI] per SD increment in GlycA, 1.65 [1.39-1.97]) and CP (1.19 [1.11-1.27]) at baseline. There were no significant associations of GlycA with incident low ABI, incident CP, or 10-year change in ABI or CP score. We identified 110 incident cases of PAD after 79 590 person-years. The hazard ratio (95% CI) of incident PAD per SD increment in GlycA was 1.38 (1.14-1.66). In conclusion, GlycA was associated with prevalent low ABI, prevalent CP, and incident PAD after a median of 14 years.
BenjaminEJViraniSSCallawayCWet al.Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.
2.
NiiranenTJVasanRS. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Expert Rev Cardiovasc Ther. 2016;14(7):855–69.
3.
LibbyP. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278–89.
4.
DuprezDAOtvosJSanchezOAMackeyRHTracyRJacobsDRJr. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62(7):1020–31.
5.
RidkerPMEverettBMThurenTet al.Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.
6.
CriquiMHMcClellandRLMcDermottMMet al.The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56(18):1506–12.
7.
O’NealWTEfirdJTNazarianSAlonsoAHeckbertSRSolimanEZ. Peripheral arterial disease and risk of atrial fibrillation and stroke: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001270.
8.
CriquiMHLangerRDFronekAet al.Mortality over a period of 10 years in patients with peripheral arterial disease. New Engl J Med. 1992;326(6):381–6.
9.
GomezCR. Carotid plaque morphology and risk for stroke. Stroke. 1990;21(1):148–51.
10.
PolakJFSzkloMKronmalRAet al.The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013;2(2):e000087.
11.
GepnerADYoungRDelaneyJAet al.Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2015;8(1).
12.
AbdellaouiAAl-KhaffafH. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007;34(1):18–22.
13.
TzoulakiIMurrayGDLeeAJRumleyALoweGDFowkesFG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: edinburgh artery study. Circulation. 2005;112(7):976–83.
14.
FolsomARPankowJSTracyRPet al.Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001;88(2):112–7.
15.
ChapmanCMLBeilbyJPMcQuillanBMThompsonPLHungJ. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke. 2004;35(7):1619–24.
16.
van der MeerIMde MaatMPMHakAEet al.C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam Study. Stroke. 2002;33(12):2750–5.
17.
AmmiratiEMoroniFNorataGDMagnoniMCamiciPG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:718329.
18.
OtvosJDShalaurovaIWolak-DinsmoreJet al.GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714–23.
19.
BensonEATibuakuuMZhaoDet al.Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: the multi-ethnic study of atherosclerosis. Clin Cardiol. 2018;41(11):1439–45.
20.
TibuakuuMFashanuOEZhaoDet al.GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. AIDS. 2019;33(3):547–57.
21.
EzeigweAFashanuOEZhaoDet al.The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2019;282:91–99.
22.
DirrichsTPenzkoferTReinartzSDKrausTMahnkenAHKuhlCK. Extracoronary thoracic and coronary artery calcifications on chest CT for lung cancer screening: association with established cardiovascular risk factors—the “CT-Risk” trial. Acad Radiol. 2015;22(7):880–9.
23.
WagenknechtLELangefeldCDFreedmanBICarrJJBowdenDW. A comparison of risk factors for calcified atherosclerotic plaque in the coronary, carotid, and abdominal aortic arteries: the diabetes heart study. Am J Epidemiol. 2007;166(3):340–7.
24.
BildDEBluemkeDABurkeGLet al.Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871–81.
25.
WheltonSPNarlaVBlahaMJet al.Association between resting heart rate and inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-6, and fibrinogen) (from the multi-ethnic study of atherosclerosis). Am J Cardiol. 2014;113(4):644–9.
26.
InkerLASchmidCHTighiouartHet al.Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.
27.
WasselCLBerardiCPankowJSet al.Soluble P-selectin predicts lower extremity peripheral artery disease incidence and change in the ankle brachial index: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239(2):405–11.
28.
VidulaHLiuKCriquiMHet al.Metabolic syndrome and incident peripheral artery disease - the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;243(1):198–203.
29.
TattersallMCGassettAKorcarzCEet al.Predictors of carotid thickness and plaque progression during a decade: the multi-ethnic study of atherosclerosis. Stroke. 2014;45(11):3257–62.
30.
FowkesFGMurrayGDButcherIet al;Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208.
31.
YeboahJMcClellandRLPolonskyTSet al.Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–95.
32.
GepnerADYoungRDelaneyJAet al.Comparison of carotid plaque score and coronary artery calcium score for predicting cardiovascular disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2017;6(2):pii:e005179.
33.
HazarikaSAnnexBH. Biomarkers and genetics in peripheral artery disease. Clin Chem. 2017;63(1):236–44.
34.
CookeJPWilsonAM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol. 2010;55(19):2017–23.
35.
OrmsethMJChungCPOeserAMet al.Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther. 2015;17(1):117.
36.
McGarrahRWKellyJPCraigDMet al.A novel protein glycan-derived inflammation biomarker independently predicts cardiovascular disease and modifies the association of HDL subclasses with mortality. Clin Chem. 2017;63(1):288–96.
37.
AkinkuolieAOBuringJERidkerPMMoraS. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3(5):e001221.
38.
GruppenEGRiphagenIJConnellyMAOtvosJDBakkerSJDullaartRP. GlycA, a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PLoS One. 2015;10(9):e0139057.
39.
AkinkuolieAOGlynnRJPadmanabhanLRidkerPMMoraS. Circulating n-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the JUPITER trial. J Am Heart Assoc. 2016;5(7):pii:e003822.
40.
JoshiAALermanJBAberraTMet al.GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016;119(11):1242–53.
41.
RitchieSCWurtzPNathAPet al.The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 2015;1(4):293–301.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
